BrainStorm Reports Positive Phase 2a Trial Results

January 11, 2015 | The Israeli company BrainStorm Cell Therapeutics announced positive results from the Phase 2a clinical trial of the company’s NurOwn treatment for ALS. The trial, conducted on 14 patients at Jerusalem’s Hadassah Medical Center. achieved its primary endpoint by demonstrating that NurOwn is a safe treatment and well tolerated. In addition, the company reports that all of the subjects in the study received clinical benefit from the NurOwn treatments, with some seeing the slowing of the progression of their condition as well as a decrease in the severity of the condition’s symptoms. BrainStorm works to create viable stem cell treatments for advanced neurodegenerative disorders such as ALS, Lou Gehrig’s disease, multiple sclerosis and Parkinson’s disease.